Sociedad Americana de Hirudoterapia

Improving Mechanical Circulatory Support Outcomes in Failing Bidirectional Glenn Physiology

Retrospective analysis published in Pediatric Cardiology (2024)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportEnsayos clínicosDesarrollo de fármacosKobayashi RL et al. · Pediatric Cardiology, 2024

Abstract

There remains high morbidity and mortality with mechanical circulatory support (MCS) in failing bidirectional Glenn (BDG) physiology. We performed a retrospective analysis of children with BDG physiology supported with MCS before and after 2018. Fourteen patients met inclusion criteria (median age 1.5 years, weight 9 kg). Prior to 2018 (n = 7), with variable anticoagulation and strategies including pulsatile VAD, continuous flow VAD, and extracorporeal membrane oxygenation (ECMO), 3 (43%) of patients were transplanted with a total of 536 patient-days of support (median 59 days). Major hemocompatability-related adverse event (MHRAE) rate was 63 per 100 patient-months. After 2018 (n = 7), using a staged support strategy (ECMO to pulsatile VAD) and bivalirudin anticoagulation, 5 (71%) patients were transplanted with a total of 1260 patient-days of support (median 188 days) and MHRAE rate of 24 per 100 patient-months. Despite challenging physiology, we have observed improved survival and reduced MHRAE despite longer support duration.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansRetrospective StudiesInfantExtracorporeal Membrane OxygenationHeart-Assist DevicesMaleFemaleChild, PreschoolFontan ProcedureChildHeart TransplantationHeart Defects, Congenital

Resumen

Children with failing bidirectional Glenn physiology on MCS; the post-2018 strategy combining staged ECMO-to-pulsatile-VAD support with bivalirudin anticoagulation reduced major hemocompatibility adverse events from 63 to 24 per 100 patient-months despite longer support duration.

Por qué esto importa para la hirudoterapia

This retrospective analysis examined outcomes in 14 children with failing bidirectional Glenn physiology who required mechanical circulatory support, comparing strategies before and after 2018. After 2018, a staged support strategy using bivalirudin anticoagulation was associated with improved survival, longer support duration, and reduced hemocompatibility-related adverse events. The abstract does not mention hirudin, leeches, hirudotherapy, or any connection to the leech secretome. While bivalirudin is thematically adjacent to leech-derived anticoagulant research, the study itself involves no leeches, no leech-derived products in their natural form, and no hirudotherapy techniques, so its direct relevance to ASH's domain is limited at best.

Citación

Improving Mechanical Circulatory Support Outcomes in Failing Bidirectional Glenn Physiology.

Kobayashi RL et al. · Pediatric Cardiology, 2024

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.